HeartSciences (HSCSW) EBITDA (2021 - 2026)

HeartSciences (HSCSW) has reported EBITDA for 6 consecutive years, with -$2.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA fell 32.08% year-over-year to -$2.5 million; the trailing twelve-month figure through Apr 2026 stood at -$8.4 million (down 0.62% YoY), and the FY2026 full-year result was -$8.4 million, down 0.72% from the prior year.
• EBITDA eased to -$2.5 million in Q2 2026 per HSCSW's latest filing, from -$2.1 million in the prior quarter.
• Across five years, EBITDA topped out at -$1.1 million in Q1 2022 and bottomed at -$2.5 million in Q2 2026.
• Historically, EBITDA has averaged -$1.8 million across 5 years, with a median of -$1.9 million in 2025.
• The sharpest annual moves came in 2022 and 2023: EBITDA slumped 112.04% in 2022, then grew 19.17% in 2023.
• Over 5 years, EBITDA stood at -$1.8 million in 2022, then grew by 11.55% to -$1.6 million in 2023, then dropped by 26.44% to -$2.0 million in 2024, then retreated by 4.45% to -$2.1 million in 2025, then decreased by 22.33% to -$2.5 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$2.5 million, -$2.1 million, and -$1.9 million for Q2 2026, Q4 2025, and Q3 2025 respectively.